Transcelerate Biopharma Inc

“During 2024, the board of directors of the corporation approved amending the bylaws of the corporation to: (a) increase from five (5) to seven (7) the number of board seats to be filled by directors who are representatives of the tier i members who are not charter members, and accordingly to increase the total number of directors from 22 to 24 to reflect such increase; and (b) adjust the membership tier eligibility thresholds as described in line 6 below.”

“The members of the corporation consist of such firms and corporations that are approved for membership from time to time by the board of directors or its designees in accordance with the policies and procedures of the corporation. The corporation has the following categories of members: a. Tier i members - to be eligible for tier i membership, a firm or corporation must be a pharmaceutical or biotechnology company with an annual budget for research and development in excess of an amount equal to $3.3 billion as of january 1, 2024, which amount shall thereafter be adjusted for inflation in accordance with the u.s. Cpi index (the "tier i threshold"). The adjusted tier i threshold shall be announced to the members periodically by the finance committee or the board of directors. Eligibility for tier i membership is established based upon the average of a company's publically available research and development expenditures over the preceding three (3) year period. The initial tier i members are further defined as the "charter members." b. Tier ii members - to be eligible for tier ii membership, a firm or corporation must be a pharmaceutical or biotechnology company with an annual budget for research and development that is less than the tier i threshold but more than an amount equal to $134 million as of january 1, 2024, which amount shall thereafter be adjusted for inflation in accordance with the u.s. Cpi index (the "tier ii threshold"). The adjusted tier ii threshold shall be announced to the members periodically by the finance committee or the board of directors.. Eligibility for tier ii membership will be established based upon the average of a company's publically available research and development expenditures over the preceding three (3) year period. C. Associate members - to be eligible for associate membership, a firm or corporation must be a pharmaceutical or biotechnology company with an annual budget for research and development that is less than the tier ii threshold.”

“The board of directors shall be comprised of up to twenty-four (24) directors; provided that: (i) ten (10) seats are filled by directors who are representatives of the charter members; (ii) up to seven (7) additional seats shall be filled by directors who are representatives of the tier i members who are not charter members; (iii) up to six (6) seats shall be filled by directors who are representatives of the tier ii members; and (iv) one (1) seat shall be filled by the chief executive officer of the corporation. The corporation's bylaws state that directors shall be elected or appointed, as applicable, annually at the annual meeting of members and shall serve until the following annual meeting of members and until their successors are elected or appointed, as applicable, and qualified. Each charter member shall have the right to appoint a representative of the charter member to serve as a charter member director. Tier i at-large directors shall be elected by a plurality vote of the tier i members, which include the charter members. Tier ii directors shall be elected by a plurality vote of the tier ii members. The ceo director shall serve ex-officio, for so long as he or she shall hold the office of chief executive officer. Each tier i member shall be entitled to three (3) votes at every meeting of members on matters which tier i members are entitled to vote. Each tier ii member shall be entitled to one (1) vote at every meeting of members on matters which tier ii members are entitled to vote. Associate members shall be entitled to notice of and to attend meetings of the members but shall not be entitled to vote at such meetings. Notwithstanding the above, in order to be eligible to vote, a member must be in good standing and its dues and assessments paid in full.”

“The finance committee and management review and approve the form 990. The form is then distributed to all members of the board for their review before filing with the internal revenue service.”

“Each director and officer of the corporation is required to annually acknowledge the conflict of interest policy, affirming that such person has received, read and understands, and agreed to comply with the conflict of interest policy.”

“The organization's executive compensation committee, consisting of independent directors, annually reviews and approves the ceo's compensation package. The ceo approves the compensation for the chief operating officer, and all other key employees.”

“The organization's governing documents, financial statements, conflict of interest policy and other corporate policies are available upon request.”

“The total number of volunteers of 27, encompasses all active board member throughout the calendar year.”

“Project management fees: program service expenses 11,209,160. Management and general expenses 0. Fundraising expenses 0. Total expenses 11,209,160. External contractor support: program service expenses 1,959,060. Management and general expenses 210,229. Fundraising expenses 0. Total expenses 2,169,289. Communications fees: program service expenses 83,415. Management and general expenses 1,007,225. Fundraising expenses 0. Total expenses 1,090,640.”